

Contents

1	Interfacial Physics for Water in Biology	1
1.1	Physics of the Biological Interface	1
1.2	Water in Biology: A Molecular Stare	3
1.3	Interfacial Tension of Biological Water	6
1.4	Variational Thermodynamics for the Biomolecular Interface	10
1.5	The Aqueous Interface from a Structure-Centric Perspective	18
1.6	Dehydrons Promote Protein Associations: A Structural Perspective	22
1.7	Epistructural Physics of the Protein Interface	25
1.8	Statistical Mechanics Apparatus for Drug-Target Associations	28
1.9	The Principles of Epistructural Physics Translate into the Architecture of Soluble Proteins	31
1.10	Why Epistructural Physics?	39
1.11	Problems	41
	References	43
2	Dielectric Structure of Aqueous Interfaces: From Classical Non-Debye Electrostatics to a Quantum Theory of Interfacial Tension	47
2.1	Interfacial Tension Stored as Non-Debye Polarization Energy	48
2.2	Non-Debye Dielectric Structure of the Aqueous Interface for a Soluble Protein	52
2.3	Epistructural Physics Reveals a Chemical Functionality for the Aqueous Interface	55
2.4	Packing Defects as Catalytic Enablers	61

2.5	A Quantum Theory of Interfacial Tension and Its Experimental Verification	63
2.6	Problems	69
	References	69
3	Solution to the Protein Folding Problem	71
3.1	Protein Folding as a Many-Body Problem	72
3.2	Cooperativity Arises from Hydrogen-Bond Wrapping	75
3.3	Cooperative Folding Pathways	78
3.4	Improving Wrapping Along Folding Pathways	82
3.5	Dielectric Modulation by the Folding Protein	87
3.6	The Dehydronic Field Steers the Folding Process	91
3.7	The Principle of Minimal Epiststructural Distortion in Protein Folding	92
3.8	Both Structural and Epiststructural Perspectives Are Necessary to Solve the Protein Folding Problem	99
3.9	Discussion Forum: The Futile Search for Protein Folding Intermediates	99
3.10	Problems	100
	References	102
4	Epiststructural Dynamics of Biological Water	105
4.1	Dynamic Singularities of Biomolecular Interfaces	105
4.2	Dehydrons Impact the Dynamics of the Aqueous Interface	107
4.3	De-wetting Propensities at the Protein-Water Interface	109
4.4	Aqueous Interface as Blueprint for Drug Design	113
4.5	Dehydron-Heated Interfacial Water	114
4.6	Problems	117
	References	119
5	Dehydron-Rich Proteins in the Order-Disorder Twilight Zone	121
5.1	Dehydron Clusters and the Order-Disorder Twilight	122
5.2	Semiclassical Dielectrics at Dehydron Sites on the Aqueous Interface	124
5.3	Semiclassical Treatment of Dielectric Modulation of Interfacial Water Around Dehydrons	127
5.4	Dielectric Modulation by Dehydrons in the p53 DNA-Binding Domain	129
5.5	Proteins with Dehydron Clusters	131
5.6	Inferring Dehydrons from Protein Sequence: Water-Exposed Backbone and Disorder Propensity	135
5.7	Misfolding and Aggregation: Flagrant Violation of the Architectural Golden Rule for Protein Structure	139
5.8	Problems	144
	References	149

6	Dehydron as a Marker for Molecular Evolution: Lessons for the Drug Designer	151
6.1	Molecular Evolution for the Drug Designer	152
6.2	Dehydron Patterns Across Orthologous Proteins: Hallmarks of Non-adaptive Traits	153
6.3	Natural Selection and Dehydron Patterns	155
6.4	Inefficient Selection in Humans: An Epistructural View of the Coping Mechanism	157
6.4.1	Expression Patterns Segregating Paralog Proteins	158
6.4.2	Dehydron Enrichment Enhances Dosage Imbalance	161
6.5	Human Capacitance to Cope with the Impact of Dosage Imbalances	166
6.6	Fitness Catastrophes for the Human Species Are the Consequence of Interactome Complexity	167
6.7	Molecular Evolutionary Insights for the Drug Designer: An Epistructural Perspective	170
6.8	Dehydron-Based Non-adaptive Evolutionary Technology	171
6.9	Dehydron Richness Above Unicellular Levels Creates a Structural Dependence Exploited to Evolve Multicellularity	172
6.10	Problems	178
	References	178
7	Catalytic Role of Dehydrons in Soluble Proteins: Biological Chemistry of Frustrated Interfacial Water	181
7.1	Catalytic Dehydrons	182
7.2	Dehydrons as Quasi-Reactants in Biological Chemistry	186
7.3	The Dehydron as a Catalytic Engine	190
7.4	Quantum Mechanics of Proton Transfer Events Involving Dehydrons	191
7.5	Quantum Mechanical Treatment of the Protein-Water Interface	192
7.6	Dehydron Chemistry	194
7.7	Frustration-Related Biological Chemistry	201
7.8	Problems	213
	References	214
8	Epistructural Selectivity Filters for Molecular Targeted Therapy	217
8.1	Controlling Drug Specificity: A Therapeutic Imperative	218
8.2	Epistucture-Based Drug Design	222
8.3	Poor Dehydron Wrappers Make Poor Drugs	225

8.4	The Biomolecular Interface as a Selectivity Filter	225
8.5	Implementing an Epistruce-Based Drug Design	226
8.6	Selectivity of Epistruce-Based Drug Designs	232
8.7	Targeting Dehydrons to Selectively Block Protein Functions	232
8.8	Caveats in Targeting Dehydrons in Floppy Regions	233
8.9	Epistruce Thermal Dynamics Filters for Drug Specificity	234
8.10	Problems	236
	References	236
9	Epistruce Re-engineering of <i>Imatinib</i> to Eliminate Adverse Side Effects	239
9.1	Imatinib Re-engineering with a Higher Safety Bar	239
9.2	Epistruce Blueprint for Imatinib Redesign	240
9.3	Epistruce Thermal Dynamics for In Silico Assessment of the Efficacy of Imatinib Wrapping Variant WBZ_4	247
9.4	Test-Tube Validation of the Engineered Specificity in Wrapping Imatinib Variant WBZ_4	250
9.5	<i>In vitro</i> Assays for Imatinib Wrapping Variant WBZ_4	251
9.6	<i>In Vitro</i> Assay of Selective Anticancer Activity of the Wrapping Design	255
9.7	Enhanced Safety Tested in Animal Models of Gastrointestinal Stromal Tumor	256
9.8	Controlled Specificity Through Epistruce Design	262
9.9	Problems	262
	References	264
10	Epistruce Informatics for the Drug Designer	267
10.1	Epistruce Selectivity Filter for Drug Design	268
10.2	Epistruce Comparative Analysis of the Human Kinome	269
	10.2.1 Sequence-Based Dehydron Inference	269
	10.2.2 Epistruce Alignment of Targetable Regions Across the Human Kinome	270
10.3	Pharmacological Relevance of the Epistruce Analysis	271
10.4	Epistruce Target Library for the Human Kinome	277
10.5	Specificity-Promoting Target Features	278
10.6	Epistruce Target Library as a Biotechnological Resource	283
10.7	Epistruce Analysis for Personalized Molecular Medicine	285
10.8	Virtual Screening of Chemical Libraries Based on Epistruce Bioinformatics	289
10.9	Problems	302
	References	303

11 Drug-Target Associations Inducing Protein Folding	305
11.1 Induced Folding: The <i>Bête Noire</i> of Structure-Based Drug Design	306
11.2 Wrapping the Floppy Protein Target in a Controllable Way	306
11.3 Crating Floppy Regions in Drug Targets	310
11.4 Target Conformational Dynamics as Selectivity Filter for Drug Design	314
11.5 Kinase Inhibitor Design Based on Dynamic Information	315
11.6 Induced Structural Disruption: Designing Drugs by Boosting the Conformational Entropy of the Target Protein	316
11.7 Problems	317
References	320
12 Drug Combinations to Enhance Therapeutic Efficacy and Edit Out Side Effects and Resistance to Inhibition of Drug Resistance	323
12.1 The Concept of Drug Editor for Side-Effect Removal	324
12.2 Editing Out Side Effects: Illustrations	325
12.3 Epiststructural Design of a Drug Editor	329
12.4 Proof of Concept for Therapeutic Editing	331
12.5 Editing Therapy in the Epiststructural Biology Era	334
12.6 Editing Out Resistance to Inhibition of Drug Resistance	335
12.7 Curing Cancer by Editing Out Mechanisms to Cope with Metabolic Stress	337
12.8 Problems	338
References	348
13 Epiststructure-Based Design of Drugs with Controlled Promiscuity	351
13.1 Is Cancer Systems Biology Calling for Controlled Promiscuity in Molecular Targeted Therapy?	351
13.2 Epiststructure-Based Control of Drug Promiscuity	354
13.3 Cleaning Dirty Drugs with Dehydron Filters	357
13.4 Controlling <i>Staurosporine</i> Promiscuity Through the Dehydron Filter	361
13.5 Systems Biology Broadens the Platform for Drug Discovery	368
13.6 Taming Sunitinib Promiscuity to Enhance Safety and Therapeutic Efficacy	369
13.7 The Therapeutic Paradigm of Controlled Promiscuity	373
13.8 Problems	374
References	374

14 Synergizing Engineered Immunotherapy with Molecularly Targeted Cancer Treatment	377
14.1 Molecularly Engineered Removal of Drug-Induced Immunosuppressive Effects in Anticancer Drug Therapy	377
14.2 Therapeutic Shortcomings of Immunosuppressive Anticancer Drugs	378
14.3 Immuno-Synergic Cancer Drugs	382
14.4 Therapeutic Evaluation of Immuno-Synergic Drugs	385
14.5 Anticancer Drugs to Overcome HIV-1 Induced Immunosuppression	386
14.6 Genetically Modified Adoptive Immunotherapy Synergized With Drug-Based Targeted Anticancer Treatment	387
14.7 Problems	389
References	389
15 Quantum Mechanical Concepts for Epistuctural Drug Design	393
15.1 Quantum Mechanical Approach to Epistuctural Drug Design	394
15.2 Halogen Bond Synergizing with Dehydron Wrapping: A Novel Motif in Drug Design	395
15.3 QM-Based Redesign of <i>Imatinib</i> to Overcome Drug Resistance	396
15.4 Problems	398
References	401
16 Structure-Based Drug Discovery Without Structure: Working Around the Paradox to Disrupt Protein-Protein Associations	403
16.1 Therapeutic Disruption of Protein-Protein Interfaces	404
16.2 Therapeutic Inhibition of Protein-Protein Associations with Unknown Complex Structure	405
16.3 Binding Hot Spots and Dehydron-Rich Epitopes	406
16.4 Identifying Binding Epitopes Using a Sequence-Based Predictor	407
16.5 Learning Technologies to Discover Epitopes for Protein Associations in the Absence of Structure	409
16.6 Dehydron Epitopes Activate Phosphorylation-Susceptible Residues	410
16.7 Structure-Based Discovery of Drug Leads in the Absence of Target Structure	411
16.8 Problems	413
References	414

17 Episturctural Drug Design to Treat Cancer Metastasis and the Associated Drug Resistance	417
17.1 Optimized FAK Inhibitor to Treat Cancer Metastasis	417
17.2 Overcoming Drug Resistance in the Anti-FAK Treatment of Cancer Metastasis	421
17.3 Problems	424
References	425
Epilogue	427
Appendix A	433
Appendix B	445
Index	475

<http://www.springer.com/978-3-319-30851-7>

Physics at the Biomolecular Interface
Fundamentals for Molecular Targeted Therapy

Fernández, A.

2016, XV, 483 p. 295 illus., 208 illus. in color.,
Hardcover

ISBN: 978-3-319-30851-7